PSPadmapriya Sathiyanathan

Padmapriya Sathiyanathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Padmapriya Sathiyanathan has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Simon McKenzie Cool

    Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore

    4 shared publications
  • Alexander Lezhava

    Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore

    3 shared publications
  • Ling Ling

    Institute of Molecular and Cell Biology, A*STAR, Singapore

    3 shared publications
  • Victor Nurcombe

    Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

    3 shared publications
  • Clarissa L. L. Tan

    Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

    2 shared publications
  • Lawrence W. Stanton

    Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

    2 shared publications

Latest Publications

  • Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion

    by Akshaya Srinivasan, Padmapriya Sathiyanathan, Lu Yin, Tong Ming Liu, Alan Lam, Maanasa Ravikumar, Raymond Alexander Alfred Smith, Han Ping Loh, Ying Zhang, Ling Ling, et al.


  • In Reply

    by Simon M. Cool, Padmapriya Sathiyanathan, Rebekah M. Samsonraj, Clarissa L. L. Tan, Ling Ling, Alexander Lezhava, Victor Nurcombe, Lawrence W. Stanton

  • Open Access

    A genomic biomarker that identifies human bone marrow-derived mesenchymal stem cells with high scalability

    by Padmapriya Sathiyanathan, Rebekah M. Samsonraj, Clarissa L. L. Tan, Ling Ling, Alexander Lezhava, Victor Nurcombe, Lawrence W. Stanton, Simon M. Cool

    Although the application of human mesenchymal stem cells (hMSCs) to repair damaged or diseased tissues has proven relatively effective, both the donor-to-donor variability in ex vivo expansion rates and the maintenance of stemness remain a bottleneck to widespread translation. Previous work from this laboratory stratified donors into those yielding hMSCs with high- or low-growth capacity; global transcriptomic analysis revealed that high-growth-capacity hMSCs were characterized by a loss of the gene encoding glutathione S-transferase theta 1 (GSTT1). These GSTT1-null hMSCs demonstrated increased proliferative rates, clonogenic potential, and longer telomeres compared with low-growth capacity hMSCs that were GSTT1-positive. Thus, this study identifies GSTT1 as a novel genomic DNA biomarker for hMSC scalability.


  • Open Access

    Establishing Criteria for Human Mesenchymal Stem Cell Potency

    by Rebekah M. Samsonraj, Bina Rai, Padmapriya Sathiyanathan, Kia Joo Puan, Olaf Rötzschke, James H. Hui, Michael Raghunath, Lawrence W. Stanton, Victor Nurcombe, Simon M. Cool

    This study sought to identify critical determinants of mesenchymal stem cell (MSC) potency using in vitro and in vivo attributes of cells isolated from the bone marrow of age- and sex-matched donors. Adherence to plastic was not indicative of potency, yet capacity for long-term expansion in vitro varied considerably between donors, allowing the grouping of MSCs from the donors into either those with high-growth capacity or low-growth capacity. Using this grouping strategy, high-growth capacity MSCs were smaller in size, had greater colony-forming efficiency, and had longer telomeres. Cell-surface biomarker analysis revealed that the International Society for Cellular Therapy (ISCT) criteria did not distinguish between high-growth capacity and low-growth capacity MSCs, whereas STRO-1 and platelet-derived growth factor receptor alpha were preferentially expressed on high-growth capacity MSCs. These cells also had the highest mean expression of the mRNA transcripts TWIST-1 and DERMO-1. Irrespective of these differences, both groups of donor MSCs produced similar levels of key growth factors and cytokines involved in tissue regeneration and were capable of multilineage differentiation. However, high-growth capacity MSCs produced approximately double the volume of mineralized tissue compared to low-growth capacity MSCs when assessed for ectopic bone-forming ability. The additional phenotypic criteria presented in this study when combined with the existing ISCT minimum criteria and working proposal will permit an improved assessment of MSC potency and provide a basis for establishing the quality of MSCs prior to their therapeutic application. Stem Cells 2015;33:1878–1891


  • Open Access

    Chaperoning HMGA2 Protein Protects Stalled Replication Forks in Stem and Cancer Cells

    by Haojie Yu, Hong Hwa Lim, Natalia O. Tjokro, Padmapriya Sathiyanathan, Suchitra Natarajan, Tian Wei Chew, Thomas Klonisch, Steven D. Goodman, Uttam Surana, Peter Dröge


  • Identification and Characterization of Mesenchymal Stem Cells Derived from the Trabecular Meshwork of the Human Eye

    by Cheryl Y. Tay, Padmapriya Sathiyanathan, Stephanie W.L. Chu, Lawrence W. Stanton, Tina T. Wong

    Mesenchymal stem cells (MSC) have been isolated from several adult human tissues. Their propensity to differentiate into cell types of connective tissue, such as osteocytes, chondrocytes, and adipocytes, suggests that MSC may function as a reserve of progenitor cells that repair and maintain healthy adult tissues. Dysfunction of the trabecular meshwork (TM), a connective tissue at the anterior region of the human eye that regulates intraocular pressure, plays a major role in the pathogenesis of glaucoma. The mechanobiology and pharmacological aspects of the TM tissue have been relatively well studied in disease states. Less well understood is if there are progenitor cells within the TM that contribute to maintenance of this tissue. In this study, we have identified and characterized an expandable population of cells that have stem cell-like properties. In particular, these cells express the markers CD73, CD90, and CD105, which are typically associated with MSC. Thus, we have named these cells TM-MSC. As further evidence that these cells are MSC, they were differentiated in vitro into adipocytes, osteocytes, and chondrocytes. Through genomic characterization, we show that TM-MSC have gene expression patterns most similar to MSC derived from other tissues. TM-MSC express genes found on adult TM tissue, suggesting that TM-MSC are progenitor cells that serve to maintain a healthy TM.


  • Open Access

    HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy

    by Heike Summer, Ou Li, Qiuye Bao, Lihong Zhan, Sabrina Peter, Padmapriya Sathiyanathan, Dana Henderson, Thomas Klonisch, Steven D. Goodman, Peter Dröge

    HMGA proteins are not translated in normal human somatic cells, but are present in high copy numbers in pluripotent embryonic stem cells and most neoplasias. Correlations between the degree of malignancy, patient prognostic index and HMGA levels have been firmly established. Intriguingly, HMGA2 is also found in rare tumor-inducing cells which are resistant to chemotherapy. Here, we demonstrate that HMGA1a/b and HMGA2 possess intrinsic dRP and AP site cleavage activities, and that lysines and arginines in the AT-hook DNA-binding domains function as nucleophiles. We also show that HMGA2 can be covalently trapped at genomic abasic sites in cancer cells. By employing a variety of cell-based assays, we provide evidence that the associated lyase activities promote cellular resistance against DNA damage that is targeted by base excision repair (BER) pathways, and that this protection directly correlates with the level of HMGA2 expression. In addition, we demonstrate an interaction between human AP endonuclease 1 and HMGA2 in cancer cells, which supports our conclusion that HMGA2 can be incorporated into the cellular BER machinery. Our study thus identifies an unexpected role for HMGA2 in DNA repair in cancer cells which has important clinical implications for disease diagnosis and therapy.